ESSA Pharma shares fell 22.6% at $6.80 yesterday. Explore masofaniten's promising Phase 1/2 results in prostate cancer treatment. Updated data, PSA reductions, and financial strength.
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPCPhase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday.
Here are some big stocks recording gains in today’s pre-market trading session.
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the
Gainers
LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves.
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
Gainers
1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its existing portfolio.